COMP <GO>
PTCT vs UNH // EV/EBITDA & P/E VALUATION
PTC Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: PTCT 9
— UNH 4
▲ EV/EBITDA & P/E VALUATION LEADER: PTCT
LAST: $64.46 (+2.29%) • MKT CAP: $5.38B
valuation
6.5x
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
valuation
16.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTCT VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PTCT | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.57% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 11.47% | +73.53 | PTCT | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 6.5x | 16.4x | -9.95 | PTCT | /valuation <GO> |
| Free Cash Flow Yield | 13.05% | 6.48% | +6.57 | PTCT | /fcf-yield <GO> |
| Operating Margin | 50.10% | 4.82% | +45.28 | PTCT | /operating-margins <GO> |
| Net Profit Margin | 39.50% | 3.14% | +36.36 | PTCT | /net-margins <GO> |
| Revenue Growth (YoY) | 114.50% | 6.46% | +108.04 | PTCT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.73 | 3.12 | -1.39 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | PTCT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.0 | 59.2 | -6.20 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.33 | +0.82 | PTCT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.6x | 17.1x | -10.49 | PTCT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.38B | $368.83B | -$363.45B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PTCT REV | UNH REV | PTCT GROSS % | UNH GROSS % | PTCT FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.73B | $447.57B | — | 88.7% | $702.3M | $16.07B |
| FY 2024 | $806.8M | $400.28B | — | 88.3% | -$114.2M | $20.70B |
| FY 2023 | $937.8M | $371.62B | — | 89.6% | -$200.6M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTCT // BETA 1.15
UNH // BETA 0.33